<DOC>
	<DOCNO>NCT00812214</DOCNO>
	<brief_summary>It hypothesize treat insomnia migraineurs , many also tension headache , prolongs total sleep time extent decrease overall headache frequency . Chronic headache sufferer also feel tired day2 , undoubtedly affect daytime functioning , hypothesize improve well prolonged total sleep time .</brief_summary>
	<brief_title>Treatment Insomnia Migraineurs</brief_title>
	<detailed_description>The objective study determine effect prolong total sleep time migraineurs insomnia overall headache frequency , daytime alertness , fatigue , function . The prolongation total sleep time accomplish bedtime administration 3 mg eszopiclone ( Lunesta™ ) , compare placebo parallel-group design .</detailed_description>
	<mesh_term>Sleep Initiation Maintenance Disorders</mesh_term>
	<mesh_term>Migraine Disorders</mesh_term>
	<mesh_term>Eszopiclone</mesh_term>
	<criteria>Subjects include study men woman , 18 64 year age ( inclusive ) , IHSII migraine with/without aura DSMIV primary insomnia ( sleep onset/sleep maintenance ) . The required migraine frequency 412 time per month , maximum 20 day headache per month , 1 month longer prior screening . The requirement regard insomnia usual , estimate total sleep time 6½ hour per night le , 1 month longer prior screening , due problem fall asleep , wake night , wake early . The sleep headache eligibility criterion confirm randomization visit basis daily diary .</criteria>
	<gender>All</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>65 Years</maximum_age>
	<verification_date>December 2008</verification_date>
	<keyword>insomnia</keyword>
	<keyword>migraine</keyword>
	<keyword>eszopiclone</keyword>
	<keyword>insomnia migraineurs</keyword>
</DOC>